Your shopping cart is currently empty

Sunitinib-platinum(IV) prodrug-1 (Complex A) is a Cisplatin-based Pt(IV) prodrug designed to be reduced to active Pt(II) in intracellular reductive conditions, while concurrently releasing a sunitinib derivative with tyrosine kinase inhibitor (TKI) activity. This compound exhibits remarkable cytotoxicity against renal cell carcinoma (RCC), inducing DNA crosslinking and apoptosis. It inhibits VEGFR/PDGFR signaling pathways, thereby suppressing tumor growth and angiogenesis, and can be used for studying RCC.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | Sunitinib-platinum(IV) prodrug-1 (Complex A) is a Cisplatin-based Pt(IV) prodrug designed to be reduced to active Pt(II) in intracellular reductive conditions, while concurrently releasing a sunitinib derivative with tyrosine kinase inhibitor (TKI) activity. This compound exhibits remarkable cytotoxicity against renal cell carcinoma (RCC), inducing DNA crosslinking and apoptosis. It inhibits VEGFR/PDGFR signaling pathways, thereby suppressing tumor growth and angiogenesis, and can be used for studying RCC. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.